
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is well-positioned for continued success, with a strong portfolio of key products in the lucrative areas of cancer, cardiometabolic, and immunology. Management's commentary suggests strong sales growth and market expansion potential. Their implementation of sustainability considerations and focus on diversity, equity, and inclusion in clinical trials demonstrates a commitment to long-term success and responsible business practices.
Bears say
Eli Lilly is experiencing pricing pressure and lower-than-expected sales for its key products, leading to a decline in its stock performance compared to its peers. The company's ability to maintain its dominant position in the obesity market and sustain its revenue growth may be challenged by growing competition and regulatory pressures. Additional risks include potential pipeline setbacks, pricing pressures, and increased drug usage which could harm the company's margins and growth potential.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares